| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 31 | 2022 | 565 | 4.020 |
Why?
|
| Amyloid beta-Peptides | 29 | 2022 | 191 | 3.720 |
Why?
|
| Cathepsin B | 13 | 2022 | 33 | 2.730 |
Why?
|
| Serum Amyloid A Protein | 19 | 2019 | 33 | 2.710 |
Why?
|
| Brain | 36 | 2020 | 2176 | 2.340 |
Why?
|
| Disease Models, Animal | 30 | 2022 | 2550 | 1.890 |
Why?
|
| Amyloid beta-Protein Precursor | 15 | 2021 | 115 | 1.860 |
Why?
|
| Animals | 150 | 2022 | 20881 | 1.820 |
Why?
|
| Diet | 5 | 2021 | 514 | 1.760 |
Why?
|
| Mice | 83 | 2022 | 8474 | 1.610 |
Why?
|
| Brain Ischemia | 20 | 2019 | 665 | 1.600 |
Why?
|
| Plaque, Amyloid | 7 | 2020 | 31 | 1.580 |
Why?
|
| Neuroprotective Agents | 11 | 2015 | 317 | 1.520 |
Why?
|
| Inflammation | 9 | 2021 | 1030 | 1.510 |
Why?
|
| Fruit | 4 | 2019 | 86 | 1.460 |
Why?
|
| Vegetables | 4 | 2019 | 76 | 1.460 |
Why?
|
| Cysteine Proteinase Inhibitors | 5 | 2014 | 73 | 1.290 |
Why?
|
| Ischemic Attack, Transient | 12 | 2008 | 167 | 1.280 |
Why?
|
| Microglia | 7 | 2019 | 143 | 1.270 |
Why?
|
| Amyloid Precursor Protein Secretases | 9 | 2021 | 59 | 1.240 |
Why?
|
| Memory Disorders | 4 | 2020 | 111 | 1.220 |
Why?
|
| Mice, Transgenic | 25 | 2022 | 1033 | 1.180 |
Why?
|
| Dietary Supplements | 8 | 2021 | 332 | 1.180 |
Why?
|
| Mice, Inbred C57BL | 36 | 2019 | 2791 | 1.160 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2019 | 105 | 1.140 |
Why?
|
| Amyloidosis | 10 | 2003 | 48 | 1.130 |
Why?
|
| Neurons | 23 | 2020 | 881 | 1.080 |
Why?
|
| Reperfusion Injury | 9 | 2015 | 320 | 1.050 |
Why?
|
| Oligopeptides | 5 | 2019 | 152 | 1.020 |
Why?
|
| Brain Injuries | 7 | 2015 | 268 | 1.010 |
Why?
|
| Cerebrovascular Circulation | 10 | 2020 | 296 | 1.010 |
Why?
|
| Memory | 6 | 2017 | 214 | 0.990 |
Why?
|
| Spinal Cord Injuries | 7 | 2017 | 551 | 0.980 |
Why?
|
| RNA, Messenger | 33 | 2012 | 1664 | 0.960 |
Why?
|
| Gene Expression Regulation | 20 | 2016 | 1293 | 0.900 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 244 | 0.810 |
Why?
|
| Behavior, Animal | 6 | 2019 | 470 | 0.800 |
Why?
|
| Aspartic Acid Endopeptidases | 6 | 2021 | 47 | 0.800 |
Why?
|
| Rats | 36 | 2020 | 5300 | 0.760 |
Why?
|
| Phytochemicals | 1 | 2021 | 6 | 0.760 |
Why?
|
| Nutritional Status | 2 | 2019 | 112 | 0.740 |
Why?
|
| Mice, Knockout | 29 | 2022 | 1692 | 0.730 |
Why?
|
| Neprilysin | 4 | 2008 | 55 | 0.700 |
Why?
|
| Astrocytes | 6 | 2019 | 270 | 0.680 |
Why?
|
| Receptors, Calcitriol | 2 | 2010 | 49 | 0.680 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 396 | 0.670 |
Why?
|
| Inflammasomes | 1 | 2019 | 39 | 0.670 |
Why?
|
| Calcitriol | 3 | 2010 | 106 | 0.660 |
Why?
|
| Tauopathies | 1 | 2018 | 6 | 0.650 |
Why?
|
| Peptide Fragments | 12 | 2014 | 483 | 0.640 |
Why?
|
| Leucine | 4 | 2014 | 41 | 0.640 |
Why?
|
| Cholecalciferol | 4 | 2012 | 143 | 0.640 |
Why?
|
| Presenilin-1 | 5 | 2020 | 28 | 0.630 |
Why?
|
| Apolipoproteins | 6 | 2000 | 51 | 0.630 |
Why?
|
| Physical Endurance | 1 | 2018 | 38 | 0.630 |
Why?
|
| Recovery of Function | 6 | 2019 | 506 | 0.610 |
Why?
|
| Apoptosis | 13 | 2015 | 1641 | 0.610 |
Why?
|
| Maze Learning | 8 | 2019 | 138 | 0.610 |
Why?
|
| Fibroblast Growth Factors | 3 | 2018 | 51 | 0.600 |
Why?
|
| Nanoparticles | 3 | 2019 | 254 | 0.590 |
Why?
|
| Cancer Vaccines | 2 | 2016 | 61 | 0.590 |
Why?
|
| Transcription, Genetic | 12 | 2015 | 562 | 0.580 |
Why?
|
| Male | 54 | 2020 | 37321 | 0.570 |
Why?
|
| Cerebral Cortex | 6 | 2015 | 415 | 0.570 |
Why?
|
| Random Allocation | 5 | 2019 | 442 | 0.570 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2016 | 50 | 0.550 |
Why?
|
| Hippocampus | 12 | 2013 | 471 | 0.550 |
Why?
|
| Skin | 2 | 2010 | 451 | 0.540 |
Why?
|
| Bottle-Nosed Dolphin | 4 | 2010 | 86 | 0.540 |
Why?
|
| Plant Extracts | 1 | 2017 | 122 | 0.530 |
Why?
|
| Oxidative Stress | 10 | 2017 | 718 | 0.530 |
Why?
|
| Brain Infarction | 3 | 2013 | 54 | 0.520 |
Why?
|
| Learning | 2 | 2017 | 186 | 0.510 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 236 | 0.500 |
Why?
|
| Superoxide Dismutase | 4 | 2013 | 149 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2020 | 2083 | 0.490 |
Why?
|
| Glioma | 1 | 2016 | 140 | 0.480 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 240 | 0.470 |
Why?
|
| Apolipoproteins E | 7 | 2002 | 92 | 0.470 |
Why?
|
| Antioxidants | 2 | 2015 | 304 | 0.470 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 75 | 0.470 |
Why?
|
| Methylmercury Compounds | 2 | 2014 | 19 | 0.470 |
Why?
|
| Genetic Vectors | 10 | 2008 | 312 | 0.460 |
Why?
|
| Amyloid | 5 | 2019 | 39 | 0.460 |
Why?
|
| Contusions | 1 | 2013 | 11 | 0.450 |
Why?
|
| Motor Activity | 7 | 2020 | 621 | 0.450 |
Why?
|
| Obesity | 1 | 2021 | 1076 | 0.440 |
Why?
|
| Enzymes, Immobilized | 1 | 2013 | 11 | 0.440 |
Why?
|
| Humans | 63 | 2022 | 68618 | 0.410 |
Why?
|
| Antibodies | 1 | 2013 | 241 | 0.400 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 371 | 0.400 |
Why?
|
| Diterpenes | 1 | 2012 | 42 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 626 | 0.400 |
Why?
|
| Cathepsins | 2 | 2011 | 37 | 0.390 |
Why?
|
| Aging | 2 | 2017 | 911 | 0.390 |
Why?
|
| Gene Expression | 11 | 2008 | 770 | 0.390 |
Why?
|
| Blood Pressure | 2 | 2016 | 1451 | 0.390 |
Why?
|
| Axons | 3 | 2018 | 139 | 0.390 |
Why?
|
| NF-kappa B | 6 | 2021 | 432 | 0.390 |
Why?
|
| Protease Inhibitors | 2 | 2010 | 76 | 0.380 |
Why?
|
| Cysteine Endopeptidases | 3 | 2007 | 39 | 0.370 |
Why?
|
| Adenoviridae | 7 | 2002 | 295 | 0.370 |
Why?
|
| Laser Therapy | 1 | 2011 | 54 | 0.370 |
Why?
|
| Encephalitis | 3 | 2008 | 43 | 0.360 |
Why?
|
| Protein Precursors | 6 | 2012 | 105 | 0.360 |
Why?
|
| Stroke | 10 | 2018 | 2163 | 0.360 |
Why?
|
| Nerve Growth Factor | 4 | 2020 | 54 | 0.360 |
Why?
|
| Glucose | 3 | 2021 | 307 | 0.360 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2016 | 507 | 0.360 |
Why?
|
| Lipoproteins, HDL | 8 | 2002 | 113 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 234 | 0.350 |
Why?
|
| Drug Design | 1 | 2010 | 107 | 0.350 |
Why?
|
| Ketones | 2 | 2020 | 24 | 0.350 |
Why?
|
| Magnesium Chloride | 1 | 2009 | 8 | 0.340 |
Why?
|
| Mitochondria | 7 | 2015 | 643 | 0.340 |
Why?
|
| Spinal Cord | 3 | 2014 | 244 | 0.340 |
Why?
|
| Receptors, Immunologic | 4 | 2004 | 72 | 0.340 |
Why?
|
| Nerve Regeneration | 4 | 2017 | 42 | 0.340 |
Why?
|
| Vitamin D | 4 | 2019 | 516 | 0.340 |
Why?
|
| Time Factors | 15 | 2020 | 4655 | 0.330 |
Why?
|
| Protein Kinases | 4 | 1993 | 122 | 0.330 |
Why?
|
| Mutation | 4 | 2012 | 1213 | 0.330 |
Why?
|
| Transcriptional Activation | 2 | 2009 | 226 | 0.330 |
Why?
|
| Cell Line | 16 | 2014 | 1752 | 0.330 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2019 | 58 | 0.320 |
Why?
|
| Lipoproteins | 2 | 2000 | 161 | 0.320 |
Why?
|
| Cells, Cultured | 20 | 2014 | 2673 | 0.320 |
Why?
|
| Cell Survival | 11 | 2019 | 901 | 0.320 |
Why?
|
| Complement Pathway, Alternative | 3 | 2015 | 69 | 0.320 |
Why?
|
| Proto-Oncogenes | 5 | 1992 | 37 | 0.310 |
Why?
|
| Biomarkers | 5 | 2019 | 1593 | 0.310 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 134 | 0.300 |
Why?
|
| Receptors, Estrogen | 3 | 2016 | 142 | 0.300 |
Why?
|
| Membrane Proteins | 4 | 2015 | 617 | 0.300 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2008 | 105 | 0.290 |
Why?
|
| Blotting, Northern | 11 | 2002 | 189 | 0.290 |
Why?
|
| Gerbillinae | 13 | 1999 | 156 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2014 | 1745 | 0.280 |
Why?
|
| Enkephalins | 5 | 1998 | 89 | 0.260 |
Why?
|
| Serum Amyloid P-Component | 3 | 2000 | 4 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 615 | 0.260 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 1992 | 317 | 0.250 |
Why?
|
| Stem Cells | 4 | 2010 | 248 | 0.250 |
Why?
|
| Models, Biological | 4 | 2019 | 981 | 0.240 |
Why?
|
| Calcium | 7 | 2010 | 929 | 0.240 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 186 | 0.240 |
Why?
|
| Cerebral Infarction | 3 | 2003 | 103 | 0.230 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 329 | 0.230 |
Why?
|
| Middle Cerebral Artery | 1 | 2004 | 57 | 0.230 |
Why?
|
| Dopamine | 2 | 2021 | 474 | 0.220 |
Why?
|
| Female | 27 | 2020 | 38074 | 0.220 |
Why?
|
| Neurogenesis | 2 | 2017 | 32 | 0.220 |
Why?
|
| Butylene Glycols | 2 | 2020 | 3 | 0.220 |
Why?
|
| Diet, Ketogenic | 2 | 2020 | 5 | 0.220 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 2 | 2020 | 6 | 0.220 |
Why?
|
| 3-Hydroxybutyric Acid | 2 | 2020 | 6 | 0.220 |
Why?
|
| Ornithine Decarboxylase | 3 | 1994 | 17 | 0.220 |
Why?
|
| Molecular Sequence Data | 13 | 2011 | 1447 | 0.220 |
Why?
|
| Lipopolysaccharides | 4 | 2021 | 455 | 0.220 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 2020 | 54 | 0.220 |
Why?
|
| Sphingosine N-Acyltransferase | 2 | 2015 | 62 | 0.220 |
Why?
|
| Cell Culture Techniques | 3 | 2009 | 189 | 0.210 |
Why?
|
| Tyrosine | 3 | 1998 | 196 | 0.210 |
Why?
|
| Kainic Acid | 3 | 2015 | 44 | 0.210 |
Why?
|
| PrPC Proteins | 1 | 2022 | 3 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 4 | 2014 | 290 | 0.210 |
Why?
|
| Brain Chemistry | 4 | 2000 | 173 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2003 | 411 | 0.200 |
Why?
|
| Signal Transduction | 5 | 2018 | 2689 | 0.200 |
Why?
|
| Regeneration | 2 | 2015 | 105 | 0.200 |
Why?
|
| Amino Acid Sequence | 12 | 2011 | 1083 | 0.200 |
Why?
|
| Cell Hypoxia | 2 | 2009 | 92 | 0.190 |
Why?
|
| Neopterin | 1 | 2021 | 2 | 0.190 |
Why?
|
| Oligodendroglia | 2 | 2010 | 107 | 0.190 |
Why?
|
| Liver | 5 | 2002 | 1118 | 0.190 |
Why?
|
| Guinea Pigs | 3 | 2011 | 124 | 0.190 |
Why?
|
| Lipoproteins, LDL | 3 | 2002 | 343 | 0.180 |
Why?
|
| Genetic Therapy | 3 | 2017 | 291 | 0.180 |
Why?
|
| Serotonin | 1 | 2021 | 144 | 0.180 |
Why?
|
| Reactive Oxygen Species | 4 | 2002 | 499 | 0.180 |
Why?
|
| Cytokines | 4 | 2018 | 866 | 0.180 |
Why?
|
| Lentivirus | 4 | 2008 | 35 | 0.180 |
Why?
|
| Nogo Receptor 1 | 1 | 2020 | 2 | 0.180 |
Why?
|
| Nogo Proteins | 1 | 2020 | 2 | 0.180 |
Why?
|
| Growth Cones | 1 | 2020 | 6 | 0.180 |
Why?
|
| Arterial Pressure | 1 | 2020 | 47 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 9 | 2009 | 532 | 0.180 |
Why?
|
| Estrogen Receptor alpha | 4 | 2016 | 65 | 0.180 |
Why?
|
| Neocortex | 1 | 2000 | 17 | 0.170 |
Why?
|
| Interleukin-2 | 1 | 2000 | 133 | 0.170 |
Why?
|
| Acetoacetates | 1 | 2019 | 2 | 0.170 |
Why?
|
| Epilepsy, Absence | 1 | 2019 | 3 | 0.170 |
Why?
|
| Peptides | 5 | 2011 | 455 | 0.170 |
Why?
|
| Cyclic AMP | 2 | 2020 | 223 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2020 | 631 | 0.170 |
Why?
|
| Estradiol | 3 | 2007 | 176 | 0.170 |
Why?
|
| Protein Kinase C | 1 | 2021 | 270 | 0.170 |
Why?
|
| Dipeptides | 3 | 2014 | 89 | 0.170 |
Why?
|
| Spleen | 5 | 2007 | 301 | 0.170 |
Why?
|
| Enterococcus faecalis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Chitosan | 1 | 2019 | 11 | 0.170 |
Why?
|
| Micelles | 1 | 2019 | 43 | 0.170 |
Why?
|
| Apolipoprotein A-I | 4 | 2002 | 29 | 0.170 |
Why?
|
| Zinc Oxide | 1 | 2019 | 18 | 0.170 |
Why?
|
| Colitis | 1 | 2000 | 156 | 0.160 |
Why?
|
| Hypertension | 2 | 2020 | 1535 | 0.160 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2019 | 11 | 0.160 |
Why?
|
| Videotape Recording | 1 | 2019 | 43 | 0.160 |
Why?
|
| Hindlimb Suspension | 1 | 2018 | 11 | 0.160 |
Why?
|
| Nutrition Policy | 1 | 2019 | 44 | 0.160 |
Why?
|
| Spatial Learning | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cholesterol | 4 | 2008 | 331 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 195 | 0.160 |
Why?
|
| PPAR delta | 1 | 2018 | 14 | 0.160 |
Why?
|
| Synaptosomes | 4 | 2007 | 57 | 0.160 |
Why?
|
| Swimming | 1 | 2018 | 38 | 0.160 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 51 | 0.160 |
Why?
|
| Trauma Severity Indices | 1 | 2018 | 80 | 0.160 |
Why?
|
| Behavioral Symptoms | 1 | 2018 | 32 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 34 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 48 | 0.160 |
Why?
|
| Sirtuin 1 | 1 | 2018 | 47 | 0.160 |
Why?
|
| Frontal Lobe | 2 | 2018 | 156 | 0.160 |
Why?
|
| Muscle Strength | 1 | 2018 | 62 | 0.160 |
Why?
|
| tau Proteins | 1 | 2018 | 61 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 320 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 107 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2012 | 1040 | 0.150 |
Why?
|
| Kallikrein-Kinin System | 1 | 2018 | 18 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2000 | 231 | 0.150 |
Why?
|
| Receptors, Bradykinin | 1 | 2018 | 50 | 0.150 |
Why?
|
| Eating | 1 | 2018 | 119 | 0.150 |
Why?
|
| Drug Liberation | 1 | 2017 | 17 | 0.150 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 22 | 0.150 |
Why?
|
| Estrogens | 2 | 2016 | 173 | 0.150 |
Why?
|
| Up-Regulation | 3 | 2008 | 682 | 0.150 |
Why?
|
| Kinins | 1 | 2018 | 109 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 627 | 0.150 |
Why?
|
| Receptors, Complement 3d | 2 | 2015 | 45 | 0.150 |
Why?
|
| Rats, Inbred F344 | 1 | 2017 | 104 | 0.140 |
Why?
|
| Risk-Taking | 1 | 2018 | 210 | 0.140 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 13 | 0.140 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2017 | 19 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 90 | 0.140 |
Why?
|
| Glycoproteins | 5 | 2000 | 238 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 434 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 142 | 0.140 |
Why?
|
| Motor Skills | 1 | 2017 | 88 | 0.140 |
Why?
|
| Seizures | 1 | 2019 | 279 | 0.140 |
Why?
|
| Cell Line, Transformed | 3 | 2009 | 100 | 0.140 |
Why?
|
| Sleep | 1 | 2018 | 263 | 0.140 |
Why?
|
| Body Weight | 1 | 2018 | 554 | 0.140 |
Why?
|
| Reaction Time | 2 | 2019 | 170 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 778 | 0.130 |
Why?
|
| Genetic Linkage | 1 | 1996 | 90 | 0.130 |
Why?
|
| Sirtuin 3 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Peroxidase | 1 | 2016 | 40 | 0.130 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2016 | 106 | 0.130 |
Why?
|
| Memory, Short-Term | 2 | 2008 | 79 | 0.130 |
Why?
|
| Sea Lions | 1 | 2015 | 8 | 0.130 |
Why?
|
| Gene Targeting | 1 | 2015 | 58 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2016 | 144 | 0.130 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 58 | 0.130 |
Why?
|
| Lymphocyte Activation | 2 | 2015 | 397 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-fos | 6 | 1996 | 114 | 0.130 |
Why?
|
| Age Factors | 4 | 2012 | 1864 | 0.130 |
Why?
|
| Gene Transfer Techniques | 3 | 2008 | 173 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 307 | 0.130 |
Why?
|
| Proteomics | 2 | 2015 | 246 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2015 | 714 | 0.130 |
Why?
|
| Nicotine | 1 | 1998 | 350 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 435 | 0.120 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 1994 | 7 | 0.120 |
Why?
|
| Microelectrodes | 1 | 2014 | 16 | 0.120 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 20 | 0.120 |
Why?
|
| Brain Damage, Chronic | 1 | 1994 | 25 | 0.120 |
Why?
|
| Eflornithine | 1 | 1994 | 15 | 0.120 |
Why?
|
| DNA | 7 | 2003 | 597 | 0.120 |
Why?
|
| Brain Edema | 3 | 1999 | 50 | 0.120 |
Why?
|
| Lipid Peroxidation | 7 | 2002 | 94 | 0.120 |
Why?
|
| Exploratory Behavior | 3 | 2004 | 79 | 0.120 |
Why?
|
| Neurites | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cattle | 9 | 2014 | 475 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 176 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 167 | 0.120 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 16 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2015 | 102 | 0.120 |
Why?
|
| Neoplasms | 2 | 2016 | 1667 | 0.120 |
Why?
|
| Tissue Distribution | 5 | 2000 | 282 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 18 | 0.120 |
Why?
|
| Multigene Family | 2 | 1994 | 93 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2014 | 51 | 0.120 |
Why?
|
| Bioprinting | 1 | 2014 | 11 | 0.120 |
Why?
|
| Vaccination | 1 | 2016 | 189 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2016 | 525 | 0.120 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 3 | 0.120 |
Why?
|
| S100 Proteins | 2 | 1991 | 42 | 0.120 |
Why?
|
| Printing, Three-Dimensional | 1 | 2014 | 31 | 0.120 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 1851 | 0.120 |
Why?
|
| Alkaline Ceramidase | 1 | 2014 | 35 | 0.120 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 335 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2016 | 384 | 0.110 |
Why?
|
| Down-Regulation | 3 | 2019 | 447 | 0.110 |
Why?
|
| Intestine, Small | 3 | 2019 | 89 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2013 | 266 | 0.110 |
Why?
|
| Homeostasis | 4 | 2020 | 291 | 0.110 |
Why?
|
| Oncogenes | 3 | 1992 | 71 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 334 | 0.110 |
Why?
|
| Transfection | 4 | 2010 | 782 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2012 | 292 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2012 | 498 | 0.110 |
Why?
|
| Neurotrophin 3 | 1 | 2012 | 7 | 0.110 |
Why?
|
| Tachykinins | 1 | 2012 | 8 | 0.110 |
Why?
|
| Neurofilament Proteins | 1 | 2012 | 20 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 4 | 1993 | 107 | 0.100 |
Why?
|
| Ganglia, Spinal | 1 | 2012 | 29 | 0.100 |
Why?
|
| Interphase | 2 | 1991 | 19 | 0.100 |
Why?
|
| Embryo, Mammalian | 3 | 2009 | 176 | 0.100 |
Why?
|
| Patch-Clamp Techniques | 2 | 2010 | 204 | 0.100 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2012 | 46 | 0.100 |
Why?
|
| Tissue Engineering | 1 | 2014 | 212 | 0.100 |
Why?
|
| Infarction | 1 | 2012 | 17 | 0.100 |
Why?
|
| Kinetics | 5 | 2017 | 1047 | 0.100 |
Why?
|
| Caspase 3 | 2 | 2010 | 233 | 0.100 |
Why?
|
| Vimentin | 1 | 1992 | 47 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2012 | 25 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2017 | 7029 | 0.100 |
Why?
|
| Spinal Cord Diseases | 1 | 2012 | 23 | 0.100 |
Why?
|
| Estrogen Receptor beta | 3 | 2007 | 19 | 0.100 |
Why?
|
| Sphingosine | 1 | 2014 | 315 | 0.100 |
Why?
|
| Cathepsin L | 2 | 2011 | 10 | 0.100 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1992 | 92 | 0.100 |
Why?
|
| Secretory Vesicles | 1 | 2011 | 6 | 0.100 |
Why?
|
| Aplysia | 1 | 1991 | 1 | 0.100 |
Why?
|
| Invertebrate Hormones | 1 | 1991 | 4 | 0.100 |
Why?
|
| Ganglia | 1 | 1991 | 6 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 114 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 384 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2012 | 61 | 0.100 |
Why?
|
| Blood-Brain Barrier | 3 | 2003 | 99 | 0.100 |
Why?
|
| Blood | 2 | 1988 | 40 | 0.100 |
Why?
|
| Decompressive Craniectomy | 1 | 2011 | 3 | 0.100 |
Why?
|
| Prostate | 1 | 2012 | 116 | 0.100 |
Why?
|
| NFI Transcription Factors | 1 | 2011 | 6 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 102 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2013 | 247 | 0.090 |
Why?
|
| Myelitis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Complement Pathway, Classical | 1 | 2010 | 22 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2000 | 1174 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 160 | 0.090 |
Why?
|
| Secretory Pathway | 1 | 2010 | 6 | 0.090 |
Why?
|
| Complement C3 | 2 | 2011 | 101 | 0.090 |
Why?
|
| Cholesterol, HDL | 3 | 2000 | 112 | 0.090 |
Why?
|
| Neuropeptides | 1 | 1991 | 106 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 26 | 0.090 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 113 | 0.090 |
Why?
|
| Corpus Striatum | 1 | 1992 | 279 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 1992 | 158 | 0.090 |
Why?
|
| Cell Death | 3 | 2022 | 329 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2011 | 145 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2010 | 234 | 0.090 |
Why?
|
| Congo Red | 2 | 2000 | 2 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 659 | 0.090 |
Why?
|
| Xenopus laevis | 1 | 1990 | 60 | 0.090 |
Why?
|
| Methamphetamine | 1 | 1991 | 132 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2015 | 29 | 0.090 |
Why?
|
| Genes, fos | 3 | 1996 | 22 | 0.090 |
Why?
|
| Silver Nitrate | 2 | 2000 | 6 | 0.080 |
Why?
|
| Atlantic Ocean | 1 | 2009 | 22 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2004 | 742 | 0.080 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 52 | 0.080 |
Why?
|
| Receptors, Glucagon | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hybrid Cells | 1 | 2009 | 18 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 434 | 0.080 |
Why?
|
| Vaccines | 1 | 2009 | 21 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 511 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2009 | 39 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 786 | 0.080 |
Why?
|
| Hippophae | 1 | 2008 | 1 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2009 | 99 | 0.080 |
Why?
|
| Triglycerides | 2 | 2020 | 184 | 0.080 |
Why?
|
| Ceramides | 2 | 2015 | 578 | 0.080 |
Why?
|
| Acute-Phase Proteins | 2 | 1998 | 13 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 149 | 0.080 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 63 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.080 |
Why?
|
| Gliosis | 1 | 2008 | 51 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2009 | 114 | 0.080 |
Why?
|
| Neurotoxins | 2 | 1999 | 30 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 1996 | 357 | 0.080 |
Why?
|
| Integrins | 1 | 2008 | 115 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 6 | 1994 | 95 | 0.080 |
Why?
|
| Collagen | 2 | 1988 | 636 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2008 | 91 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 86 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 1998 | 32 | 0.080 |
Why?
|
| Receptors, Opioid, delta | 1 | 2008 | 37 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 3 | 2004 | 19 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 19 | 0.070 |
Why?
|
| Nitric Oxide | 2 | 2008 | 382 | 0.070 |
Why?
|
| Mice, Inbred Strains | 2 | 2000 | 181 | 0.070 |
Why?
|
| Oxygen | 2 | 2019 | 386 | 0.070 |
Why?
|
| Second Messenger Systems | 1 | 2007 | 53 | 0.070 |
Why?
|
| Gene Knockout Techniques | 2 | 2022 | 61 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 81 | 0.070 |
Why?
|
| Monocytes | 2 | 2000 | 210 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 117 | 0.070 |
Why?
|
| P-Selectin | 1 | 2006 | 16 | 0.070 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2008 | 183 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 200 | 0.070 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 700 | 0.070 |
Why?
|
| Blotting, Southern | 2 | 1998 | 67 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 260 | 0.070 |
Why?
|
| Microscopy, Electron | 4 | 2000 | 351 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 124 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 2223 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2009 | 272 | 0.070 |
Why?
|
| Phosphorylation | 3 | 1993 | 1200 | 0.060 |
Why?
|
| Protein Isoforms | 3 | 2000 | 246 | 0.060 |
Why?
|
| Acute-Phase Reaction | 3 | 2000 | 10 | 0.060 |
Why?
|
| Polymers | 2 | 2017 | 244 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2019 | 431 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2004 | 26 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 652 | 0.060 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2004 | 22 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 30 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1174 | 0.060 |
Why?
|
| Software | 2 | 2019 | 418 | 0.060 |
Why?
|
| DNA Adducts | 1 | 2003 | 7 | 0.060 |
Why?
|
| Mutagens | 1 | 2003 | 18 | 0.060 |
Why?
|
| Chick Embryo | 2 | 2014 | 379 | 0.060 |
Why?
|
| Phenanthrenes | 1 | 2003 | 18 | 0.060 |
Why?
|
| Indomethacin | 2 | 2002 | 107 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 2 | 2001 | 69 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2014 | 147 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 196 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2004 | 368 | 0.060 |
Why?
|
| Models, Animal | 2 | 2020 | 252 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 48 | 0.050 |
Why?
|
| Protein Transport | 2 | 2020 | 280 | 0.050 |
Why?
|
| Purkinje Cells | 2 | 1993 | 18 | 0.050 |
Why?
|
| DNA Repair | 1 | 2003 | 127 | 0.050 |
Why?
|
| Receptors, Lipoprotein | 1 | 2002 | 11 | 0.050 |
Why?
|
| Receptors, Laminin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2022 | 5 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2002 | 9 | 0.050 |
Why?
|
| Prion Proteins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 172 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1992 | 138 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2000 | 165 | 0.050 |
Why?
|
| Apolipoprotein E3 | 2 | 2002 | 7 | 0.050 |
Why?
|
| Synapsins | 1 | 2002 | 11 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 2000 | 134 | 0.050 |
Why?
|
| Laminin | 1 | 2022 | 62 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 213 | 0.050 |
Why?
|
| Metalloendopeptidases | 2 | 1993 | 67 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2004 | 269 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 167 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 282 | 0.050 |
Why?
|
| Transcription Factors | 3 | 1991 | 753 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2003 | 954 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 1991 | 71 | 0.050 |
Why?
|
| Regional Blood Flow | 2 | 2014 | 168 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2003 | 120 | 0.050 |
Why?
|
| Ovary | 2 | 1993 | 99 | 0.050 |
Why?
|
| RNA | 2 | 2000 | 171 | 0.050 |
Why?
|
| Chickens | 2 | 2014 | 232 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2001 | 29 | 0.050 |
Why?
|
| Semantics | 1 | 2001 | 37 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 2000 | 219 | 0.050 |
Why?
|
| Rotarod Performance Test | 1 | 2020 | 3 | 0.050 |
Why?
|
| Ketosis | 1 | 2020 | 3 | 0.050 |
Why?
|
| Mental Recall | 1 | 2001 | 72 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2000 | 18 | 0.050 |
Why?
|
| Gene Library | 2 | 2006 | 68 | 0.050 |
Why?
|
| Rodentia | 1 | 2020 | 27 | 0.050 |
Why?
|
| Zinc Sulfate | 1 | 2000 | 4 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2000 | 11 | 0.050 |
Why?
|
| Metallothionein | 1 | 2000 | 20 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 44 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2000 | 26 | 0.050 |
Why?
|
| Visual Cortex | 1 | 2001 | 67 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 66 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 166 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 5731 | 0.040 |
Why?
|
| Sodium Cyanide | 1 | 2000 | 3 | 0.040 |
Why?
|
| Partial Pressure | 1 | 2000 | 19 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2001 | 109 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2000 | 40 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 2000 | 29 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2001 | 125 | 0.040 |
Why?
|
| Dantrolene | 1 | 2000 | 8 | 0.040 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2000 | 16 | 0.040 |
Why?
|
| PC12 Cells | 1 | 2020 | 36 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2020 | 19 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 1999 | 567 | 0.040 |
Why?
|
| Intestines | 1 | 2000 | 114 | 0.040 |
Why?
|
| Complement Activation | 2 | 2011 | 145 | 0.040 |
Why?
|
| Leukotriene C4 | 1 | 1999 | 7 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 18 | 0.040 |
Why?
|
| Arachidonic Acid | 1 | 1999 | 86 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2000 | 78 | 0.040 |
Why?
|
| Rabbits | 1 | 2000 | 509 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 78 | 0.040 |
Why?
|
| Base Sequence | 5 | 1994 | 1015 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2000 | 260 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 75 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 174 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2000 | 72 | 0.040 |
Why?
|
| Chelating Agents | 1 | 1999 | 47 | 0.040 |
Why?
|
| Caseins | 1 | 1999 | 19 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 1999 | 107 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 119 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1998 | 59 | 0.040 |
Why?
|
| Biofilms | 1 | 2019 | 72 | 0.040 |
Why?
|
| Amyloid Neuropathies | 1 | 1998 | 1 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1999 | 112 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 330 | 0.040 |
Why?
|
| Haplorhini | 1 | 1998 | 44 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 331 | 0.040 |
Why?
|
| Vascular Stiffness | 1 | 2018 | 31 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2007 | 791 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 98 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2019 | 107 | 0.040 |
Why?
|
| Nucleic Acids | 1 | 1998 | 16 | 0.040 |
Why?
|
| Child | 2 | 2019 | 6405 | 0.040 |
Why?
|
| Nitrates | 1 | 1998 | 61 | 0.040 |
Why?
|
| Antigens, CD | 1 | 1998 | 230 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 1993 | 195 | 0.040 |
Why?
|
| Protein Binding | 2 | 2015 | 1027 | 0.040 |
Why?
|
| Heart Rate | 1 | 2000 | 568 | 0.040 |
Why?
|
| Goals | 1 | 2018 | 65 | 0.040 |
Why?
|
| Albumins | 1 | 2017 | 72 | 0.040 |
Why?
|
| Synapses | 3 | 2010 | 222 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 85 | 0.040 |
Why?
|
| Solutions | 1 | 2017 | 115 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 1997 | 9 | 0.040 |
Why?
|
| Vascular Calcification | 1 | 2018 | 131 | 0.040 |
Why?
|
| Neuroglia | 2 | 2014 | 136 | 0.040 |
Why?
|
| Cations | 1 | 2017 | 51 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 492 | 0.040 |
Why?
|
| Liposomes | 1 | 2017 | 107 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2017 | 150 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2000 | 332 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 52 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1993 | 85 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2016 | 18 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 371 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 137 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 1996 | 136 | 0.030 |
Why?
|
| Surface-Active Agents | 1 | 2017 | 57 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 254 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 161 | 0.030 |
Why?
|
| Aged | 6 | 2012 | 14862 | 0.030 |
Why?
|
| Water | 1 | 2017 | 230 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 188 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 298 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 1996 | 79 | 0.030 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2015 | 4 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2015 | 9 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 12 | 0.030 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2015 | 12 | 0.030 |
Why?
|
| White Matter | 1 | 2018 | 174 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1996 | 73 | 0.030 |
Why?
|
| Reperfusion | 2 | 1996 | 78 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cognition | 1 | 1999 | 513 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2012 | 371 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 271 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 848 | 0.030 |
Why?
|
| Putrescine | 1 | 1994 | 17 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 1994 | 6 | 0.030 |
Why?
|
| Granulosa Cells | 2 | 1993 | 21 | 0.030 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 2 | 1991 | 2 | 0.030 |
Why?
|
| Protein Biosynthesis | 2 | 1993 | 181 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 157 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2014 | 55 | 0.030 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 23 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 24 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 25 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2014 | 33 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 17 | 0.030 |
Why?
|
| Molecular Weight | 3 | 2007 | 358 | 0.030 |
Why?
|
| Chromaffin Cells | 1 | 2014 | 2 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 35 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 45 | 0.030 |
Why?
|
| Cerebellar Cortex | 1 | 1993 | 4 | 0.030 |
Why?
|
| Middle Aged | 4 | 2018 | 21147 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 1994 | 305 | 0.030 |
Why?
|
| Apoproteins | 1 | 1993 | 11 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 2 | 1991 | 114 | 0.030 |
Why?
|
| Dactinomycin | 3 | 1992 | 31 | 0.030 |
Why?
|
| Species Specificity | 2 | 1994 | 303 | 0.030 |
Why?
|
| Cell Division | 2 | 1992 | 541 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 324 | 0.030 |
Why?
|
| Genistein | 1 | 1993 | 26 | 0.030 |
Why?
|
| Prostaglandins | 1 | 1993 | 65 | 0.030 |
Why?
|
| Isoflavones | 1 | 1993 | 31 | 0.030 |
Why?
|
| Aluminum | 1 | 1992 | 21 | 0.030 |
Why?
|
| Complement C6 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2012 | 4 | 0.030 |
Why?
|
| Intracellular Membranes | 3 | 1999 | 86 | 0.030 |
Why?
|
| Osteocalcin | 1 | 1992 | 37 | 0.030 |
Why?
|
| Phenols | 1 | 1993 | 73 | 0.030 |
Why?
|
| Complement C1q | 1 | 2012 | 18 | 0.030 |
Why?
|
| Complement Factor B | 1 | 2012 | 19 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2012 | 20 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1992 | 11 | 0.030 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2012 | 13 | 0.030 |
Why?
|
| CD59 Antigens | 1 | 2012 | 30 | 0.030 |
Why?
|
| Genes, jun | 1 | 1992 | 13 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2012 | 30 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1992 | 37 | 0.030 |
Why?
|
| Cell Shape | 1 | 2012 | 37 | 0.030 |
Why?
|
| Autoradiography | 1 | 1992 | 94 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2358 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2014 | 201 | 0.030 |
Why?
|
| Growth Substances | 2 | 1990 | 77 | 0.030 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2012 | 4 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 2891 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2012 | 26 | 0.030 |
Why?
|
| Osteoblasts | 1 | 1992 | 99 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1991 | 19 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 3187 | 0.030 |
Why?
|
| Cysteine Proteases | 1 | 2011 | 4 | 0.020 |
Why?
|
| Culture Media | 2 | 2008 | 155 | 0.020 |
Why?
|
| FMRFamide | 1 | 1991 | 1 | 0.020 |
Why?
|
| Aldehydes | 2 | 2002 | 34 | 0.020 |
Why?
|
| Nitrogen Oxides | 1 | 1991 | 7 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 1991 | 42 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 376 | 0.020 |
Why?
|
| G1 Phase | 1 | 1991 | 42 | 0.020 |
Why?
|
| S Phase | 1 | 1991 | 38 | 0.020 |
Why?
|
| Mice, Mutant Strains | 2 | 2003 | 166 | 0.020 |
Why?
|
| Free Radicals | 1 | 1991 | 65 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 151 | 0.020 |
Why?
|
| Plasma | 1 | 1991 | 58 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 1991 | 69 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1991 | 43 | 0.020 |
Why?
|
| Cyclic N-Oxides | 2 | 2002 | 17 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 1999 | 765 | 0.020 |
Why?
|
| Proteolysis | 1 | 2011 | 97 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 172 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 940 | 0.020 |
Why?
|
| Piperazines | 1 | 1992 | 206 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 48 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2010 | 57 | 0.020 |
Why?
|
| Hydrogen Peroxide | 2 | 2001 | 168 | 0.020 |
Why?
|
| Gene Products, tat | 1 | 2010 | 4 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 28 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 285 | 0.020 |
Why?
|
| Specific Gravity | 1 | 1990 | 2 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 4 | 1992 | 95 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 1991 | 314 | 0.020 |
Why?
|
| Larva | 1 | 1990 | 39 | 0.020 |
Why?
|
| Calmodulin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.020 |
Why?
|
| Curcumin | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mammals | 1 | 1990 | 47 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 1990 | 119 | 0.020 |
Why?
|
| Locomotion | 1 | 2010 | 135 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 1990 | 64 | 0.020 |
Why?
|
| Oocytes | 1 | 1990 | 57 | 0.020 |
Why?
|
| Calpain | 1 | 2010 | 205 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 204 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1990 | 102 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 1990 | 71 | 0.020 |
Why?
|
| Venoms | 1 | 2009 | 6 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 1989 | 14 | 0.020 |
Why?
|
| Clonal Anergy | 1 | 2009 | 4 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2010 | 141 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 396 | 0.020 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2009 | 20 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2009 | 22 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1989 | 117 | 0.020 |
Why?
|
| Mesencephalon | 1 | 2009 | 41 | 0.020 |
Why?
|
| Rats, Transgenic | 1 | 2008 | 24 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Integrin alpha6beta1 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Receptors, Vitronectin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 867 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Microcirculation | 1 | 2008 | 77 | 0.020 |
Why?
|
| Action Potentials | 1 | 2010 | 223 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2008 | 50 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 101 | 0.020 |
Why?
|
| Marmota | 1 | 2008 | 4 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2008 | 200 | 0.020 |
Why?
|
| Hibernation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2008 | 72 | 0.020 |
Why?
|
| Heparin | 1 | 1989 | 205 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1196 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2008 | 103 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 218 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1989 | 312 | 0.020 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2007 | 6 | 0.020 |
Why?
|
| Hematoxylin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1991 | 493 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 18 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 1987 | 15 | 0.020 |
Why?
|
| Electron Transport | 1 | 2007 | 37 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 25 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2007 | 106 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1991 | 532 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2006 | 35 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 647 | 0.020 |
Why?
|
| Lymphoma | 1 | 1987 | 116 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 2007 | 36 | 0.020 |
Why?
|
| Complement Inactivator Proteins | 1 | 2006 | 20 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 579 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Count | 1 | 2007 | 248 | 0.020 |
Why?
|
| Pregnancy | 1 | 1992 | 2334 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 2006 | 58 | 0.020 |
Why?
|
| Immune System | 1 | 2006 | 63 | 0.020 |
Why?
|
| Immunity | 1 | 2006 | 67 | 0.020 |
Why?
|
| Spectral Karyotyping | 1 | 2005 | 4 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 852 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 1056 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 219 | 0.020 |
Why?
|
| Keratins | 1 | 2005 | 48 | 0.020 |
Why?
|
| Epidermis | 1 | 2005 | 42 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2007 | 201 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1986 | 489 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2004 | 10 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2006 | 215 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2004 | 16 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2004 | 12 | 0.020 |
Why?
|
| Pedigree | 1 | 2004 | 159 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2004 | 52 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2004 | 160 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2005 | 180 | 0.010 |
Why?
|
| MutS DNA Mismatch-Binding Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 12 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 26 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 32 | 0.010 |
Why?
|
| Lung | 1 | 1989 | 849 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 34 | 0.010 |
Why?
|
| CHO Cells | 1 | 2004 | 161 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 262 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2003 | 83 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 597 | 0.010 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2003 | 17 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 25 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 237 | 0.010 |
Why?
|
| Fetus | 1 | 2004 | 157 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 2003 | 35 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 756 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1987 | 1034 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 223 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2002 | 13 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 191 | 0.010 |
Why?
|
| Kidney | 2 | 2003 | 945 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 48 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2002 | 18 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 2 | 1993 | 196 | 0.010 |
Why?
|
| Apolipoprotein E2 | 1 | 2002 | 8 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 2 | 1993 | 7 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 214 | 0.010 |
Why?
|
| Thiobarbiturates | 1 | 2002 | 4 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2003 | 122 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2324 | 0.010 |
Why?
|
| Cellular Senescence | 2 | 1993 | 112 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 1993 | 85 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 245 | 0.010 |
Why?
|
| Ferrous Compounds | 1 | 2001 | 18 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2001 | 36 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2001 | 67 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1986 | 902 | 0.010 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2001 | 17 | 0.010 |
Why?
|
| Membrane Fluidity | 1 | 2001 | 13 | 0.010 |
Why?
|
| Visual Pathways | 1 | 2001 | 31 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 20 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2001 | 65 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2077 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 1992 | 8 | 0.010 |
Why?
|
| Thiazoles | 1 | 2001 | 95 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 386 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1553 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 597 | 0.010 |
Why?
|
| Cycloheximide | 2 | 1993 | 50 | 0.010 |
Why?
|
| Spin Labels | 1 | 2000 | 27 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 308 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 786 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 1999 | 27 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 194 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 210 | 0.010 |
Why?
|
| Face | 1 | 1999 | 46 | 0.010 |
Why?
|
| Glutathione | 1 | 2001 | 343 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2002 | 274 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 947 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2001 | 332 | 0.010 |
Why?
|
| Adult | 2 | 2012 | 21403 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1998 | 27 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1998 | 27 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1998 | 53 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2001 | 517 | 0.010 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2000 | 99 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2001 | 532 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1998 | 31 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 1997 | 10 | 0.010 |
Why?
|
| Sex Factors | 1 | 2001 | 1266 | 0.010 |
Why?
|
| Probability | 1 | 1996 | 245 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 420 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 1995 | 32 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1995 | 88 | 0.010 |
Why?
|
| Tubocurarine | 1 | 1994 | 3 | 0.010 |
Why?
|
| Genetic Code | 1 | 1994 | 4 | 0.010 |
Why?
|
| DNA Probes | 1 | 1994 | 57 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 251 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 4848 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 201 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1993 | 10 | 0.010 |
Why?
|
| Aromatase Inhibitors | 1 | 1993 | 17 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1993 | 41 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1993 | 71 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1993 | 62 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1992 | 26 | 0.010 |
Why?
|
| Gonadotropins, Equine | 1 | 1991 | 1 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1991 | 31 | 0.010 |
Why?
|
| Colforsin | 1 | 1991 | 42 | 0.010 |
Why?
|
| Cytosol | 1 | 1991 | 123 | 0.010 |
Why?
|
| Plasmids | 1 | 1992 | 258 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1991 | 346 | 0.010 |
Why?
|
| Ischemia | 1 | 1991 | 229 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 618 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 50 | 0.010 |
Why?
|
| Annexins | 1 | 1989 | 3 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1989 | 35 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1989 | 122 | 0.010 |
Why?
|
| Muscles | 1 | 1989 | 158 | 0.000 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1986 | 45 | 0.000 |
Why?
|
| Cell Communication | 1 | 1986 | 116 | 0.000 |
Why?
|
| Histones | 1 | 1986 | 111 | 0.000 |
Why?
|
| Actins | 1 | 1986 | 249 | 0.000 |
Why?
|